DeepMed Research

Georgetown University

🇬🇹Guatemala

Country: 🇬🇹Guatemala

Ownership: Private

Established: 1789-01-23

Employees: 5K

Market Cap: -

Website: http://www.georgetown.edu

Clinical Trials

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma
Refractory Non-Small Cell Lung Cancer

Interventions: Drug: Daratumumab
Biological: KRAS vaccine
Drug: Nivolumab

First Posted Date: 2023-08-29

Last Posted Date: 2024-02-05

Lead Sponsor: Georgetown University

Target Recruit Count: 54

Registration Number: NCT06015724

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Glucose-Guided Eating Pilot

Not Applicable

Not yet recruiting

Conditions: Prediabetes
Adolescent and Young Adult (AYA) Cancer Survivors
Postmenopausal

Interventions: Other: CGM only
Behavioral: Glucose-Guided Eating with CGM

First Posted Date: 2023-08-21

Last Posted Date: 2023-12-21

Lead Sponsor: Georgetown University

Target Recruit Count: 100

Registration Number: NCT05998460

Healthy Lifestyles: A Home Based Physical Activity Intervention in Persons Living With HIV

Not Applicable

Not yet recruiting

Conditions: Metabolic Syndrome
HIV-1-infection

Interventions: Behavioral: physical activity

First Posted Date: 2023-06-09

Last Posted Date: 2023-06-09

Lead Sponsor: Georgetown University

Target Recruit Count: 50

Registration Number: NCT05896852

Istradefylline Effect Protocol on Parkinson's Disease Tremor

Phase 4

Completed

Conditions: Parkinson Disease
Tremor

Interventions: Drug: Istradefylline Pill

First Posted Date: 2023-06-01

Last Posted Date: 2025-03-13

Lead Sponsor: Georgetown University

Target Recruit Count: 27

Registration Number: NCT05885360

Locations: 🇺🇸
Georgetown University Hospital, McLean, Virginia, United States

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer

Phase 2

Recruiting

Conditions: Metastatic Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Nab paclitaxel
Drug: Placebo
Drug: Proglumide

First Posted Date: 2023-04-24

Last Posted Date: 2024-05-17

Lead Sponsor: Georgetown University

Target Recruit Count: 30

Registration Number: NCT05827055

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States

Mindful Self-Compassion for Anxiety Disorders and Depression

Not Applicable

Recruiting

Conditions: Panic Disorder
Agoraphobia
Anxiety Disorders
Social Phobia
Major Depressive Disorder
Generalized Anxiety Disorder
Social Anxiety Disorder

Interventions: Behavioral: Mindful Self-Compassion

First Posted Date: 2023-01-04

Last Posted Date: 2024-06-07

Lead Sponsor: Georgetown University

Target Recruit Count: 40

Registration Number: NCT05671419

Locations: 🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor
KRAS Mutation-Related Tumors

Interventions: Drug: NEROFE
Drug: Doxorubicin

First Posted Date: 2022-12-22

Last Posted Date: 2025-04-08

Lead Sponsor: Georgetown University

Target Recruit Count: 24

Registration Number: NCT05661201

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2

Recruiting

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma

Interventions: Drug: BXCL701
Drug: Pembrolizumab

First Posted Date: 2022-09-29

Last Posted Date: 2025-03-24

Lead Sponsor: Georgetown University

Target Recruit Count: 43

Registration Number: NCT05558982

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis

Phase 1

Active, not recruiting

Conditions: Safety Issues
Pain
Pancreas Fibrosis

Interventions: Drug: Placebo
Drug: Proglumide

First Posted Date: 2022-09-23

Last Posted Date: 2024-02-01

Lead Sponsor: Georgetown University

Target Recruit Count: 32

Registration Number: NCT05551858

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States

Evaluating Novel Therapies in ctDNA Positive GI Cancers

Phase 3

Recruiting

Conditions: Adenocarcinoma of Biliary Tract
Colon Adenocarcinoma
Rectal Adenocarcinoma
Pancreatic Adenocarcinoma
Gastric Adenocarcinoma
Hepatocellular Carcinoma
Gallbladder Adenocarcinoma

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2022-08-01

Last Posted Date: 2025-02-13

Lead Sponsor: Georgetown University

Target Recruit Count: 20

Registration Number: NCT05482516

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy